The myocarditis risk differential for Moderna's vaccine relative to Pfizer/BioNTech's is looking better with the passage of time and more surveillance data. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
